Next Article in Journal
Immune-Associated Proteins Are Enriched in Lung Tissue-Derived Extracellular Vesicles during Allergen-Induced Eosinophilic Airway Inflammation
Previous Article in Journal
Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters
Previous Article in Special Issue
Editorial: Special Issue on “Molecular Mechanisms Regulating Osteoclastogenesis”
Article

Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity

1
Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
2
Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
3
Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
*
Authors to whom correspondence should be addressed.
Academic Editor: Giacomina Brunetti
Int. J. Mol. Sci. 2021, 22(9), 4717; https://doi.org/10.3390/ijms22094717
Received: 2 March 2021 / Revised: 26 April 2021 / Accepted: 28 April 2021 / Published: 29 April 2021
(This article belongs to the Special Issue Molecular Mechanisms Regulating Osteoclastogenesis)
Lumican, a ubiquitously expressed small leucine-rich proteoglycan, has been utilized in diverse biological functions. Recent experiments demonstrated that lumican stimulates preosteoblast viability and differentiation, leading to bone formation. To further understand the role of lumican in bone metabolism, we investigated its effects on osteoclast biology. Lumican inhibited both osteoclast differentiation and in vitro bone resorption in a dose-dependent manner. Consistent with this, lumican markedly decreased the expression of osteoclastogenesis markers. Moreover, the migration and fusion of preosteoclasts and the resorptive activity per osteoclast were significantly reduced in the presence of lumican, indicating that this protein affects most stages of osteoclastogenesis. Among RANKL-dependent pathways, lumican inhibited Akt but not MAP kinases such as JNK, p38, and ERK. Importantly, co-treatment with an Akt activator almost completely reversed the effect of lumican on osteoclast differentiation. Taken together, our findings revealed that lumican inhibits osteoclastogenesis by suppressing Akt activity. Thus, lumican plays an osteoprotective role by simultaneously increasing bone formation and decreasing bone resorption, suggesting that it represents a dual-action therapeutic target for osteoporosis. View Full-Text
Keywords: lumican; osteoclast; bone resorption; Akt signaling lumican; osteoclast; bone resorption; Akt signaling
Show Figures

Figure 1

MDPI and ACS Style

Lee, J.-Y.; Kim, D.-A.; Kim, E.-Y.; Chang, E.-J.; Park, S.-J.; Kim, B.-J. Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity. Int. J. Mol. Sci. 2021, 22, 4717. https://doi.org/10.3390/ijms22094717

AMA Style

Lee J-Y, Kim D-A, Kim E-Y, Chang E-J, Park S-J, Kim B-J. Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity. International Journal of Molecular Sciences. 2021; 22(9):4717. https://doi.org/10.3390/ijms22094717

Chicago/Turabian Style

Lee, Jin-Young, Da-Ae Kim, Eun-Young Kim, Eun-Ju Chang, So-Jeong Park, and Beom-Jun Kim. 2021. "Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity" International Journal of Molecular Sciences 22, no. 9: 4717. https://doi.org/10.3390/ijms22094717

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop